Fractyl Health, Inc. Discusses 1-Year REMAIN-1 Data on Weight Maintenance After GLP-1 Discontinuation
Fractyl Health, Inc. has released findings from their REMAIN-1 study, showcasing the effectiveness of their treatment in maintaining weight after GLP-1 therapy ends.
Editorial Staff
1 min read
Updated 1 day ago
Fractyl Health, Inc. recently discussed the results of their REMAIN-1 study, which focused on the long-term effects of their treatment on weight maintenance following the discontinuation of GLP-1 medications.
The study demonstrated that patients were able to maintain their weight effectively even after stopping GLP-1 therapy, suggesting a durable impact of the treatment.
These findings are significant for the healthcare community, as they provide insights into managing weight loss and maintenance strategies for patients who have used GLP-1 treatments.